Ex vivo generated and expanded autologous cytotoxic T cells engineered by selection/expansion to recognize TAA peptides (NY-ESO-1, MAGEA4, PRAME, Survivin, SSX) presented on HLA class I, administered as adoptive cellular immunotherapy to eradicate residual lymphoma.
Autologous cytotoxic T lymphocytes are generated and expanded ex vivo for endogenous TCR specificity to tumor‑associated antigen peptides (NY-ESO-1, MAGEA4, PRAME, Survivin, SSX) presented on HLA class I. After infusion, these CTLs recognize HLA-restricted TAA on lymphoma cells and induce targeted killing via perforin/granzyme release and cytokine-mediated effector functions to eradicate residual disease.
YES
DIRECT
Adoptively transferred TAA-specific CTLs recognize NY-ESO-1 peptide presented on HLA class I via their TCR and induce apoptosis of target cells through perforin/granzyme release (and Fas/FasL).
Ex vivo generated and expanded autologous cytotoxic T cells engineered by selection/expansion to recognize TAA peptides (NY-ESO-1, MAGEA4, PRAME, Survivin, SSX) presented on HLA class I, administered as adoptive cellular immunotherapy to eradicate residual lymphoma.
Autologous cytotoxic T lymphocytes are generated and expanded ex vivo for endogenous TCR specificity to tumor‑associated antigen peptides (NY-ESO-1, MAGEA4, PRAME, Survivin, SSX) presented on HLA class I. After infusion, these CTLs recognize HLA-restricted TAA on lymphoma cells and induce targeted killing via perforin/granzyme release and cytokine-mediated effector functions to eradicate residual disease.
YES
DIRECT
Adoptively transferred TAA-specific CTLs recognize MAGE-A4–derived peptides on HLA class I via their TCRs and directly kill target cells by perforin/granzyme-mediated cytolysis (and Fas/FasL), with supportive cytokine effects.
Ex vivo generated and expanded autologous cytotoxic T cells engineered by selection/expansion to recognize TAA peptides (NY-ESO-1, MAGEA4, PRAME, Survivin, SSX) presented on HLA class I, administered as adoptive cellular immunotherapy to eradicate residual lymphoma.
Autologous cytotoxic T lymphocytes are generated and expanded ex vivo for endogenous TCR specificity to tumor‑associated antigen peptides (NY-ESO-1, MAGEA4, PRAME, Survivin, SSX) presented on HLA class I. After infusion, these CTLs recognize HLA-restricted TAA on lymphoma cells and induce targeted killing via perforin/granzyme release and cytokine-mediated effector functions to eradicate residual disease.
YES
DIRECT
Infused autologous TAA-specific CTLs recognize PRAME-derived peptides presented on HLA class I via their TCR and directly kill target cells through perforin/granzyme-mediated apoptosis (and Fas/FasL).
Ex vivo generated and expanded autologous cytotoxic T cells engineered by selection/expansion to recognize TAA peptides (NY-ESO-1, MAGEA4, PRAME, Survivin, SSX) presented on HLA class I, administered as adoptive cellular immunotherapy to eradicate residual lymphoma.
Autologous cytotoxic T lymphocytes are generated and expanded ex vivo for endogenous TCR specificity to tumor‑associated antigen peptides (NY-ESO-1, MAGEA4, PRAME, Survivin, SSX) presented on HLA class I. After infusion, these CTLs recognize HLA-restricted TAA on lymphoma cells and induce targeted killing via perforin/granzyme release and cytokine-mediated effector functions to eradicate residual disease.
YES
DIRECT
Infused TAA-specific CTLs recognize Survivin peptide presented on HLA class I and directly kill target cells via TCR engagement, releasing perforin/granzymes (and ancillary Fas–FasL/cytokine-mediated apoptosis).
Ex vivo generated and expanded autologous cytotoxic T cells engineered by selection/expansion to recognize TAA peptides (NY-ESO-1, MAGEA4, PRAME, Survivin, SSX) presented on HLA class I, administered as adoptive cellular immunotherapy to eradicate residual lymphoma.
Autologous cytotoxic T lymphocytes are generated and expanded ex vivo for endogenous TCR specificity to tumor‑associated antigen peptides (NY-ESO-1, MAGEA4, PRAME, Survivin, SSX) presented on HLA class I. After infusion, these CTLs recognize HLA-restricted TAA on lymphoma cells and induce targeted killing via perforin/granzyme release and cytokine-mediated effector functions to eradicate residual disease.
YES
DIRECT
Adoptively transferred TCR-native CTLs recognize SSX-derived peptides on HLA class I and directly kill target cells via perforin/granzyme-mediated cytolysis (with cytokine-mediated effects).